Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05745623 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 25, 2026 to Dec 25, 2027 Enrollment target: 55 to 70v3 Show 1 more changeShow less
    • Enrollment target: 55 to 70
  2. Primary completion date: Jun 2024 to Dec 25, 2026 Completion date: Dec 2026 to Dec 25, 2028 · Study title shortened, about 3 wordsv2 Show 2 more changesShow less
    • Completion date: Dec 2026 to Dec 25, 2028
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
Trial Details
NCT Number NCT05745623
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov